BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD

BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD

We have performed the first-ever Budget Impact Analysis (BIA) in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autological transplantation of stem cells isn’t shown. R...

Full description

Bibliographic Details
Main Authors: A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
Format: Article
Language:Russian
Published: IRBIS LLC 2015-06-01
Series:Фармакоэкономика
Subjects:
pharmacoeconomics
budget impact analysis (bia)
multiple myeloma
bendamustine
bortezomib
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/96

Similar Items

Similar Items